Search - tctmd.com

Displaying 381 - 400 of 591

Sort: Relevancy | Date

Presentation TCT 2017

SENIOR: A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES vs a BMS With Short DAPT in Patients With Coronary Artery Disease Older Than 75 Years

Presenter: Robert A. Harrington, Gregg W. Stone, Olivier Varenne

November 01, 2017

Presentation TCT 2017

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

Presenter: Azeem Latib, Gregg W. Stone

October 31, 2017

Presentation TCT 2017

FDA Perspectives on Short DAPT IDE Trials

Presenter: Mitchell W. Krucoff, P.F. Adrian Magee

October 31, 2017

Presentation TCT 2017

The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Standard vs Novel DES and DAPT Duration

Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Ajay J. Kirtane

October 31, 2017

Presentation TCT 2017

The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Appropriate Patients and DAPT Duration

Presenter: Mitchell W. Krucoff, P.F. Adrian Magee, Marie-Claude Morice

October 31, 2017

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

Presentation TCT 2017

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Roxana Mehran

October 30, 2017

Presentation TCT 2017

Utility of Genotyping and Platelet Function Testing to Guide Antiplatelet Therapy: 2017 Assessment

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Thomas Engstroem

October 30, 2017

Presentation TCT 2017

Switching to and From Cangrelor: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli

October 30, 2017

Presentation TCT 2017

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Matthew J. Price

October 30, 2017

Presentation TCT 2017

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Fabiana Rollini

October 30, 2017

Presentation TCT 2017

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Ron Waksman

October 30, 2017

Presentation TCT 2017

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies!

Presenter: John A. Bittl, Freek W.A. Verheugt, Gennaro Giustino

October 30, 2017

Presentation TCT 2017

Expanding Clinical Evidence With SYNERGY: From EVOLVE II to Real-world Registries and EVOLVE DAPT

Presenter: Ioannis Iakovou, Gert Richardt, Dean J. Kereiakes

October 30, 2017

Presentation TCT 2017

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? Yes, Based on TROPICAL-ACS, TRITON, and Other Studies!

Presenter: John A. Bittl, Freek W.A. Verheugt, Dirk Sibbing

October 30, 2017

Presentation TCT 2017

DAPT Duration After BVS: Can Evidence-Based Recommendations Be Made?

Presenter: John A. Bittl, Freek W.A. Verheugt, Davide Capodanno

October 30, 2017

Presentation TCT 2017

Debate: DAPT Duration With Contemporary DES: Short (<1 Year) DAPT for Most ACS Patients!

Presenter: John A. Bittl, Freek W.A. Verheugt, Marco Valgimigli

October 30, 2017

Presentation TCT 2017

Debate: DAPT Duration With Contemporary DES: Prolonged (>1 Year) DAPT for Most ACS Patients!

Presenter: John A. Bittl, Freek W.A. Verheugt, Robert W. Yeh

October 30, 2017

Presentation TCT 2017

Debate: Making the Case for Not Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Presenter: John A. Bittl, Freek W.A. Verheugt, Somjot S. Brar

October 30, 2017

Presentation TCT 2017

Debate: Making the Case for Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Presenter: John A. Bittl, Freek W.A. Verheugt, Dimitrios Alexopoulos

October 30, 2017

Advertisement

SENIOR: A Randomized Trial of a Bioabsorbable Polymer-Based Metallic DES vs a BMS With Short DAPT in Patients With Coronary Artery Disease Older Than 75 Years

What Is the Optimal DAPT Duration With ABSORB? Results From a Comprehensive Meta-Analysis

FDA Perspectives on Short DAPT IDE Trials

The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Standard vs Novel DES and DAPT Duration

The High-Bleeding-Risk Patient: Physician-Scientist Perspectives on Appropriate Patients and DAPT Duration

Long-term Absorb BVS Data Continue to Disappoint

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Utility of Genotyping and Platelet Function Testing to Guide Antiplatelet Therapy: 2017 Assessment

Switching to and From Cangrelor: When and How?

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Impact of Race and Sex on Platelet Reactivity and Clinical Implications

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? No, Based on HORIZONS-AMI, PLATO, PEGASUS, and Other Studies!

Expanding Clinical Evidence With SYNERGY: From EVOLVE II to Real-world Registries and EVOLVE DAPT

Debate: After PCI in ACS, Should DAPT Potency Be De-escalated Over Time? Yes, Based on TROPICAL-ACS, TRITON, and Other Studies!

DAPT Duration After BVS: Can Evidence-Based Recommendations Be Made?

Debate: DAPT Duration With Contemporary DES: Short (<1 Year) DAPT for Most ACS Patients!

Debate: DAPT Duration With Contemporary DES: Prolonged (>1 Year) DAPT for Most ACS Patients!

Debate: Making the Case for Not Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Debate: Making the Case for Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content